CAHCardinal Health, Inc.

Ticker: CAH | Current Price: $282.18 | Today's Change: +7.74% Filing Type: 8-K (Items 2.02, 7.01, 9.01) | Filed with the SEC on: November 5, 2026

---

What Happened

Cardinal Health filed an 8-K with the SEC on November 5, 2026 disclosing its first-quarter fiscal year 2027 financial results under Item 2.02 (Results of Operations and Financial Condition). The company reported revenues of $64.01 billion, net income of $450 million, and operating income of $668 million for Q1 FY2027. Diluted earnings per share came in at $1.88, with basic EPS at $1.89, reflecting meaningful bottom-line performance on a massive top-line base.

---

Why It Matters

For investors, this quarterly result puts a concrete number on Cardinal Health's scale — $64 billion in a single quarter underscores the company's position as one of the largest healthcare distribution businesses in the United States. The key practical considerations:

• Revenue scale: At $64.01 billion for the quarter, Cardinal Health is running at an annualized revenue pace well above $250 billion, confirming the sheer magnitude of its pharmaceutical and medical distribution operations.
• Profitability: Net income of $450 million on that revenue base reflects the characteristically thin but stable margins typical of large-scale healthcare distribution — operating income of $668 million shows that core operations are generating solid cash-generating capacity.
• EPS signal: Diluted EPS of $1.88 gives investors a per-share lens on the quarter's profitability, and the near-8% single-day stock move suggests the market interpreted this result favorably relative to its prior expectations.
• Market reaction: A +7.74% move on the day of this report's publication is a significant single-session gain for a company of this market capitalization, signaling that investor sentiment shifted meaningfully on these numbers.

---

Analysis

The magnitude of the market's reaction — nearly 8% on a mega-cap healthcare distributor — suggests Cardinal Health's Q1 FY2027 results came in meaningfully ahead of what the Street had anticipated, at least on one or more key metrics. At the revenue level, $64 billion in a single quarter is a substantial figure, and the combination of strong top-line performance with a net income of $450 million and operating income of $668 million indicates that Cardinal Health is not only growing its distribution volume but managing the cost structure well enough to convert that volume into earnings.

What to watch next:

• Full-year guidance: Investors will focus intently on whether management raised, maintained, or adjusted its full-year FY2027 outlook in the accompanying earnings call and materials filed under Items 7.01 and 9.01.
• Segment breakdown: Cardinal Health operates distinct Pharmaceutical and Medical segments — the split of revenue and profitability between these two will matter for understanding the quality and sustainability of the quarter's results.
• Margin trajectory: With operating income at $668 million on $64 billion in revenue, the operating margin remains in the low-single-digit percentage range, as expected for this business model. Any expansion or compression of that margin trend will be a key focus for analysts.
• Share repurchases and capital allocation: EPS figures relative to the net income number will also draw scrutiny for buyback activity that could be supporting per-share metrics.

The stock's sharp move higher reflects genuine investor enthusiasm about these results, and the bar for the remainder of FY2027 has now been set meaningfully higher.

---

Disclaimer

This report is a news and informational analysis based solely on data contained in Cardinal Health's SEC filing dated November 5, 2026, and is provided for informational purposes only. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. No rating or price target is expressed or implied. Investors should conduct their own due diligence and consult a qualified financial adviser before making investment decisions.

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/721371/000072137126000042/cah-20261105.htm